fillwise.fillwise.

Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Medication plan: estimated costs for a whole medication list

Listed in the December 27, 2023 extract; not in the current extract (September 22, 2026): Glucagon (02243297). Source: odb-formulary-ed43-extract-2023-12-27.xml; compared with odb-formulary-ed43-extract-2026-09-22.xml.

Private plan not entered. Private-plan coverage, and how it coordinates with public programs, is not determined here; the Ontario public-program lines on this page remain conditional on the entered details and the program rules.

Glucagon

Form:

2 of 2 products shown

1 Limited Use · 1 listing conditions apply

Baqsimi · DIN 02492415 · 3 mg · Nas Pd Device

Limited Use, Reason for Use code 625 requiredMarketed · checked October 5, 2026
StatusLimited Use, Reason for Use code 625 required
Write on scriptReason for Use code 625 (criteria below)
Patient paysIf the Reason for Use code is written and the criteria are met, ODB 65 and over pays: • ODB senior: $100/program-year deductible • Then up to $6.11 per prescription • Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription If the criteria are not met, ODB does not pay this product under Limited Use. [Limited Use benefit, Formulary flag]
Ontario Limited Use criteria, code 625
Reason for Use code 625 For the treatment of severe hypoglycemia (SH) reactions in patients with diabetes mellitus who are receiving insulin therapy and are at high risk for SH, when impaired consciousness precludes oral carbohydrate. Coverage limit: LU Authorization Period: 1 year
No interchangeable product listed in the Ontario extract
Baqsimi · DIN 02492415 Manufacturer: Amphastar Pharmaceuticals Inc.; listing date 2022-01-31 Health Canada: Marketed since 2024-09-23 · brand BAQSIMI · ATC H04AA01 GLUCAGON · form Powder · route Nasal · ingredients GLUCAGON 3 MG/CONTAINER · company Amphastar pharmaceuticals, inc. · schedule Ethical
Re-check Health Canada status and shortages (live) · Health Canada product record

Baqsimi: Formulary list price $160.52 per unit (the source does not state the unit; exact figure $160.5200). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02492415)

Source record
DIN 02492415: Baqsimi Raw flags: sec12=Y, sec3=Y Item: 920000739; group id 920; item number 2194; lccId 00351; manufacturer id AMP Source form: Nas Pd Device; strength: 3mg Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below Source prices (unrounded): $160.5200; ministry $160.5200 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02492415 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=98243
Shortage status: resolved shortage (ended August 12, 2025); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02492415
Shortage record checked October 6, 2026

Glucagon Injection Kit · PIN 09858279 · 1 mg/Vial · injection Pd-1mL vial (Kit)

Temporary benefitOntario PIN; no Health Canada record under this code
StatusTemporary benefit
Write on scriptcheck temporary-benefit rules below
Patient paysNot paid by ODB 65 and over; see alternatives

No Health Canada record under this code: Ontario lists it under a product identification number (PIN), not a DIN. Look up the brand's own DIN on Health Canada: https://health-products.canada.ca/dpd-bdpp/index-eng.jsp

Check Health Canada brand search
No interchangeable product listed in the Ontario extract
Glucagon Injection Kit · DIN 09858279 Manufacturer: Amphastar Pharmaceuticals Inc.; listing date 2023-09-28 No Health Canada record under this code: Ontario lists it under a product identification number (PIN), not a DIN. Look up the brand's own DIN on Health Canada: https://health-products.canada.ca/dpd-bdpp/index-eng.jsp
Re-check Health Canada status and shortages (live)

Glucagon Injection Kit: Formulary list price $280.00 per unit (the source does not state the unit; exact figure $280.0000). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Ontario PIN; see Health Canada brand lookup · Verify on the e-Formulary ↗ (DIN 09858279)

Source record
DIN 09858279: Glucagon Injection Kit Raw flags: sec3c=Y Item: 920000743; group id 919; item number 2193; lccId None; manufacturer id AMP Source form: Inj Pd-1mL Vial Pk (Kit); strength: 1mg/Vial Recorded listing: Temporary benefit (shortage substitute) Source prices (unrounded): $280.0000; ministry $280.0000 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=09858279 Look up the brand's own DIN on Health Canada: https://health-products.canada.ca/dpd-bdpp/index-eng.jsp
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=09858279
Shortage record checked October 6, 2026

Glucagon rdna origin

All strengths: General benefit; same patient cost rules

Shared coverage and patient cost rules
StatusGeneral benefit; Health Canada lists this DIN as Cancelled post market since 2024-02-29 — choose a marketed DIN from the same-category list.
Patient paysODB senior: $100/program-year deductible • Then up to $6.11 per prescription Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription

GlucaGen HypoKit · DIN 02333627 · 1 mg/Vial · injection Pd-Syr Pk

General benefit; Health Canada lists this DIN as Cancelled post market since 2024-02-29 — choose a marketed DIN from the same-category list.Discontinued February 29, 2024 · checked November 17, 2026
Write on scriptno code needed; Health Canada lists this DIN as Cancelled post market since 2024-02-29 — choose a marketed DIN from the same-category list.
No interchangeable product listed in the Ontario extract
GlucaGen HypoKit · DIN 02333627 Manufacturer: Novo Nordisk Canada Inc; listing date 2011-12-15 Health Canada: Cancelled post market since 2024-02-29 · brand GLUCAGEN HYPOKIT · ATC H04AA01 GLUCAGON · form Kit, Powder for solution · route Intramuscular · ingredients GLUCAGON (RECOMBINANT DNA ORIGIN) (GLUCAGON HYDROCHLORIDE) 1 MG/VIAL · company Novo nordisk canada inc · schedule Schedule d
Re-check Health Canada status and shortages (live) · Health Canada product record

GlucaGen HypoKit: Formulary list price $112.67 per unit (the source does not state the unit; exact figure $112.6700). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02333627)

Source record
DIN 02333627: GlucaGen HypoKit Raw flags: sec3=Y Item: 920000644; group id 921; item number 2195; lccId None; manufacturer id NOO Source form: Inj Pd-Syr Pk; strength: 1mg/Vial Recorded listing: General benefit Source prices (unrounded): $112.6700; ministry $112.6700 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02333627 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=81924
Shortage status: discontinued (February 29, 2024, reported by NOVO NORDISK CANADA INC); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02333627
Shortage record checked October 6, 2026
Health Canada lists this DIN as Cancelled post market since February 29, 2024 — choose a marketed DIN from the same-category list.

GlucaGen · DIN 02333619 · 1 mg/Vial · powder for injection, vial

General benefit; Health Canada lists this DIN as Cancelled post market since 2024-02-29 — choose a marketed DIN from the same-category list.Discontinued February 29, 2024 · checked November 17, 2026
Write on scriptno code needed; Health Canada lists this DIN as Cancelled post market since 2024-02-29 — choose a marketed DIN from the same-category list.
No interchangeable product listed in the Ontario extract
GlucaGen · DIN 02333619 Manufacturer: Novo Nordisk Canada Inc; listing date 2011-12-15 Health Canada: Cancelled post market since 2024-02-29 · brand GLUCAGEN · ATC H04AA01 GLUCAGON · form Powder for solution, Kit · route Intramuscular · ingredients GLUCAGON (RECOMBINANT DNA ORIGIN) (GLUCAGON HYDROCHLORIDE) 1 MG/VIAL · company Novo nordisk canada inc · schedule Schedule d
Re-check Health Canada status and shortages (live) · Health Canada product record

GlucaGen: Formulary list price $108.33 per unit (the source does not state the unit; exact figure $108.3300). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02333619)

Source record
DIN 02333619: GlucaGen Raw flags: sec3=Y Item: 920000643; group id 921; item number 2196; lccId None; manufacturer id NOO Source form: Inj Pd-Vial Pk; strength: 1mg/Vial Recorded listing: General benefit Source prices (unrounded): $108.3300; ministry $108.3300 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02333619 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=81923
Shortage status: discontinued (February 29, 2024, reported by NOVO NORDISK CANADA INC); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02333619
Shortage record checked October 6, 2026
Health Canada lists this DIN as Cancelled post market since February 29, 2024 — choose a marketed DIN from the same-category list.
Other drugs in the same formulary class (92:00 UNCLASSIFIED THERAPEUTIC AGENTS) and how they are covered

Matched class: 92:00 UNCLASSIFIED THERAPEUTIC AGENTS

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Public program routes: ODB 65 and over Covered without a code on the Ontario formulary: ALENDRONATE & CHOLECALCIFEROL, AZATHIOPRINE, CYCLOSPORINE, LANREOTIDE ACETATE, LEFLUNOMIDE, LEVODOPA & BENSERAZIDE, MYCOPHENOLATE SODIUM, RISPERIDONE Some products covered without a code (check the product listing): ALENDRONATE, ALLOPURINOL, AMANTADINE HCL, BROMOCRIPTINE, CLOPIDOGREL BISULFATE, LEVODOPA & CARBIDOPA, MYCOPHENOLATE MOFETIL, OCTREOTIDE, RISEDRONATE SODIUM, ROPINIROLE, SELEGILINE HCL, TAMSULOSIN HCL 92:00 UNCLASSIFIED THERAPEUTIC AGENTS

ALENDRONATE

· 28 products · Off-Formulary Interchangeable, not an ODB benefit (4), Listed, not a benefit (1), General benefit (23) · strengths: 5mg, 10mg, 70mg · Tab

ALENDRONATE & CHOLECALCIFEROL

· 6 products · General benefit · strengths: 70mg & 70mcg, 70mg & 140mcg · Tab

ALLOPURINOL

· 10 products · General benefit (6), Listed, not a benefit (4) · strengths: 100mg, 200mg, 300mg · Tab

AMANTADINE HCL

· 5 products · Listed, not a benefit (2), General benefit (3) · strengths: 100mg, 10mg/mL · Cap, O/L

AZATHIOPRINE

· 3 products · General benefit · strengths: 50mg · Tab

BROMOCRIPTINE

· 4 products · Listed, not a benefit (2), General benefit (2) · strengths: 5mg, 2.5mg · Cap, Tab

CLOPIDOGREL BISULFATE

· 19 products · General benefit (16), Off-Formulary Interchangeable, not an ODB benefit (3) · strengths: 75mg, 300mg · Tab

CYCLOSPORINE

· 8 products · General benefit · strengths: 10mg, 25mg, 50mg, 100mg, 100mg/mL · Cap, O/L

LANREOTIDE ACETATE

· 6 products · General benefit · strengths: 60mg/Syr, 90mg/Syr, 120mg/Syr · ER Pref Syr Pk

LEFLUNOMIDE

· 16 products · General benefit · strengths: 10mg, 20mg · Tab

LEVODOPA & BENSERAZIDE

· 3 products · General benefit · strengths: 50mg & 12.5mg, 100mg & 25mg, 200mg & 50mg · Cap

LEVODOPA & CARBIDOPA

· 25 products · Listed, not a benefit (5), Limited Use, codes 64, 65 (2), General benefit (18) · strengths: 100mg & 25mg, 200mg & 50mg, 100mg & 10mg, 250mg & 25mg · CR Tab, Tab Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=2026-09-22; class 92:00 and 77 more
Full class listing Related classes: Same formulary class, not same indication: class membership alone does not establish equivalent uses.
What the Health Canada label says it is for
1 INDICATIONS BAQSIMI is indicated for the treatment of severe hypoglycemic reactions which may occur in the management of insulin treated patients with diabetes mellitus, when impaired consciousness precludes oral carbohydrates. 1.1 Pediatrics Pediatrics (<18 years of age): BAQSIMI is indicated in children 4 years and above. BAQSIMI has not been studied in pediatric patients less than 4 years of age. The number of pediatric patients (4 to <18 years) included in the clinical trials is limited (n=48) (see WARNINGS AND PRECAUTIONS, Special Populations, DOSAGE AND ADMINISTRATION, ACTION AND CLINICAL PHARMACOLOGY, and CLINICAL TRIALS). 1.2 Geriatrics Geriatrics (≥65 years of age): Clinical studies of BAQSIMI did not include sufficient numbers of subjects aged 65 and over. Limited clinical trial experience with BAQSIMI has not identified differences in responses between the elderly and younger patients (see WARNINGS AND PRECAUTIONS, Special Populations; DOSAGE AND ADMINISTRATION; and ACTION AND CLINICAL PHARMACOLOGY). https://pdf.hres.ca/dpd_pm/00074561.PDF PM date: not printed or not captured Source product: BAQSIMI; DIN 02492415; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.
What the Health Canada label says it is for
Product monograph unavailable: no marketed product found

Availability

GlucaGen HypoKit · DIN 02333627 Shortage status: discontinued (2024-02-29, reported by NOVO NORDISK CANADA INC); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02333627

Check this DIN again

GlucaGen · DIN 02333619 Shortage status: discontinued (2024-02-29, reported by NOVO NORDISK CANADA INC); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02333619

Check this DIN again
Program rules and quotes
Public program routes (Ontario context; residency, health-card/OHIP requirements and enrolment must be confirmed from the quoted rules): ODB 65 and over (seniors path) Eligibility: You may qualify for the Ontario Drug Benefit (ODB) program when you turn 65 years old. (ontario.ca, August 18, 2026 ↗) Eligibility: The Ontario Drug Benefit program is for Ontario residents only and prescriptions must be filled in an Ontario pharmacy to be covered. (ontario.ca, August 18, 2026 ↗) Eligibility: Individual annual net income threshold Program year August 1, 2026 to July 31, 2027: $25,480 This applies to a senior who: does not have a spouse has a married spouse with whom they no longer live in a conjugal relationship has a spouse living in a long-term care home or community home for opportunity (ontario.ca, July 2, 2026 ↗) Eligibility: Combined annual net income requirement Program year August 1, 2026 to July 31, 2027: $42,290 This applies to a senior who has a spouse, other than a spouse described. (ontario.ca, July 2, 2026 ↗) Eligibility: See the first-year deductible table. (ontario.ca, August 18, 2026 ↗) What it pays / costs: the first $100 of total prescription costs each program year (August 1 to July 31 the following year) (ontario.ca, August 18, 2026 ↗) What it pays / costs: up to $6.11 for each prescription filled or refilled (after paying the deductible) (ontario.ca, August 18, 2026 ↗) What it pays / costs: Seniors enrolled in the Seniors Co-Payment Program have no annual deductible and a reduced co-payment of up to $2. (ontario.ca, August 18, 2026 ↗) Enrolment: "We will send you a letter about 3 months before your 65th birthday to let you know you will automatically join the Ontario Drug Benefit program on the first day of the month after you turn 65 years old." (ontario.ca, August 18, 2026 ↗) Enrolment: "To enroll in the Seniors Co-Payment Program, a senior must submit an application to that program and qualify under certain income eligibility thresholds." (ontario.ca, August 18, 2026 ↗)
First year on ODB? The deductible depends on birth month
For your first year of Ontario Drug Benefit program eligibility, depending on the month you turn 65, the deductible may be lower than $100. That’s because the amount of the deductible is based on the number of months between your official start date (the first day of the month after you turn 65) and July 31 (the last day of the Ontario Drug Benefit program year). For example, if you turned 65 on April 15, your official start date would be May 1. Counting from May 1 to July 31 your deductible for the first year would be $25. Use this chart below to see what the deductible will be in your first year:
Month you were bornAmount of first-year deductible
July$100.00
August$91.67
September$83.33
October$75.00
November$66.67
December$58.33
January$50.00
February$41.67
March$33.33
April$25.00
May$16.67
June$8.33

Ontario source · 2026-08-18